Intra-Arterial Magnesium Therapy After Mechanical Thrombectomy in Acute Ischemic Stroke

Prior treatment

• mRS\>2 caused by a history of prior stroke,
• Unsuitable for this clinical study assessed by researcher. Subjects will not be excluded if they received IV t-PA as standard of care.

Other illness

• subjects on therapeutic anticoagulation, as it is a relative contraindication to MT, and could be a confounding variable predisposing to intracranial hemorrhage including coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia \<80000/mm3;
• Second or third-degree heart block without a pacemaker in place,
• patients taking digoxin or other cardiac glycoside

Lab values

• Patient already enrolled in another experimental treatment trial. Exclusion criteria 1-3 are all contraindications to magnesium therapy,
• Severe hepatic dysfunction, severe renal dysfunction (\<30 mL/min), increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;

Other

• Positive pregnancy test;
• those undergoing MT with a TICI \<2a revascularization;
• tandem occlusion of the cervical common or internal carotid artery; and
• Technical inability to navigate micro-catheter to target clot,
• patient is on neuromuscular blocking agents including depolarizing (succinylcholine) and nondepolarizing subtypes (rocuronium, vecuronium, etc);
• patient is taking any form of CNS depressant including barbiturates, narcotics, outside the setting of anesthesia or ICU sedation

• Patient with acute cerebral ischemia due to ICA or MCA occlusion
• Major neurologic deficits: 6≤NIHSS≤20,
• Premorbid mRS 0 or 1, or 2
• Patient's clinical attending physician plans MT procedure as part of routine clinical care,
• undergo MT with a TICI 2a or better recanalization,
• Signed informed consent.